DIANT® Pharma Technology: Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors

The landscape of genetic medicine is evolving. While viral vectors have historically been widely used for gene delivery, RNA-based therapeutics, particularly those delivered via lipid nanoparticles (LNPs), are increasingly explored as an alternative approach. DIANT’s technology provides equipment designed to generate reproducible, monodispersed nanoparticles – an important aspect to enable consistent therapeutic performance and predictable biological activity.

Limitations of Traditional Viral Vectors

Adenoviruses, lentiviruses, and adeno-associated viruses (AAVs) have been widely adopted in research and clinical applications due to their efficiency and ability to support long-term gene expression. Despite their advantages, viral vectors present several challenges that limit their broader application. Immune recognition and pre-existing neutralizing antibodies can reduce vector efficacy or induce unwanted immune reactions. Cell-based production processes are complex, labor-intensive, and costly, often requiring extensive purification steps to ensure safety and quality. Furthermore, many viral vectors have limited payload capacity, restricting the types of genetic constructs that can be delivered. Regulatory concerns related to insertional mutagenesis and potential replication-competent contaminants further complicate the pathway from research to clinic. These constraints have encouraged the development of alternative drug delivery systems to meet therapeutic outcomes with fewer risks.

RNA-LNP Therapeutics: A Flexible, Transient Approach

RNA-based therapeutics delivered via LNPs offer distinct advantages in comparison to viral vectors. LNPs encapsulate RNA molecules, protecting them from enzymatic degradation and facilitating cellular uptake. Unlike integrating viral vectors, RNA delivery is transient, allowing for controlled protein expression and the option of repeated dosing. This approach mitigates concerns regarding permanent genomic integration and reduces potential long-term safety risks.

LNPs can carry diverse RNA payloads, including messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides, and CRISPR/Cas# components. This versatility supports multiple therapeutic modalities, from vaccination to different gene editing approaches and to protein replacement therapies. The transient nature of RNA expression also allows precise temporal control, which can be critical in applications such as immunomodulation or controlled gene editing where sustained expression is not required.

Compared with viral systems, RNA-LNP therapeutics benefit from advances in process technology. Continuous flow approaches allow for reproducible, scalable, and controlled particle formation. Such advanced processes naturally support meeting specifications for critical quality attributes, including particle size, surface charge, % RNA encapsulation and lipid composition, which influence biodistribution, cellular uptake, and pharmacokinetics. Iterative optimization of these parameters can be performed without fundamentally altering the processing platform, supporting flexibility across therapeutic applications.

DIANT® Pharma Provides Technology for Precision and Consistency

The therapeutic performance of LNPs is highly dependent on particle uniformity, % encapsulation and payload integrity. DIANT’s technology addresses these factors with engineered systems that ensure reproducibility and scalability across research, preclinical and clinical stages. Key features include:

  • Monodispersed Nanoparticles: DIANT’s systems produce LNPs with narrow size distributions, reducing variability between batches and improving in-vivo predictability and performance.
  • Scalable Processing: Processes optimized at laboratory scale can be translated to larger preclinical and clinical runs without compromising particle quality or RNA stability.
  • Payload Versatility: The platform accommodates a wide range of RNA types and sizes, from short interfering RNAs to long self-amplifying RNA constructs, supporting diverse therapeutic targets.
  • Controlled Formulations: DIANT® enables tuning of lipid composition, surface chemistry and particle characteristics to address specific therapeutic requirements.

By integrating precision engineering with process control, DIANT® provides a platform capable of supporting the reproducible generation of LNPs, which is essential for reliable translation from experimental studies to clinical applications.

Translational Applications

The combination of RNA flexibility and DIANT’s controlled LNP processing supports development across multiple therapeutic areas.

  • Vaccines: RNA-LNP platforms allow rapid design and formulation, enabling timely responses to emerging infectious diseases. Adjustments in LNP composition and particle characteristics can optimize immune response while maintaining tolerability.
  • Gene Editing: LNPs provide transient delivery for CRISPR/Cas components, reducing the risk of off-target effects and insertional mutagenesis. Transient expression is advantageous for applications requiring precise temporal control.
  • Protein Replacement Therapies: mRNA therapeutics can transiently produce therapeutic proteins in-vivo; circumventing challenges associated with permanent viral vector integration.
  • Oncology and Rare Diseases: Precision in particle formulation supports tissue-specific delivery and optimized dosing, extending the potential applications of RNA therapeutics in complex disease settings.

Moving Forward

RNA-LNP therapeutics represent a practical alternative to viral vectors for applications requiring transient, repeatable expression. While viral vectors may remain necessary in cases where long-term gene expression is required, LNPs offer a unique combination of versatility, safety, and quality. DIANT’s technology is engineered to provide reproducible, high-quality RNA-LNPs that supports R&D/preclinical/clinical development and suitable for commercialization.

As RNA-based therapeutics continue to advance, platforms such as DIANT’s contribute to bridging research and practical application. By focusing on reproducibility, process control, and payload versatility, DIANT® enables consistent LNP processing that can be adapted to a variety of therapeutic applications. Through this approach, DIANT’s technology provides a reliable foundation for researchers and developers to translate RNA-based strategies into practical treatments, supporting the advancement of genetic medicine with scientifically controlled and predictable tools.